摘要
目的人乳头瘤病毒16型(human papillomavirus 16,HPV16)是引起宫颈癌的主要型别,HPV16主要衣壳蛋白L1具有激活宿主免疫细胞,诱导中和抗体产生的功能。本研究旨在探讨HPV16L1基因变异与宫颈癌发生的关系。方法共纳入2015-09-30-2017-03-31昆明医科大学第三附属医院妇科89例感染HPV16的宫颈癌患者(病例组)和132名感染HPV16无宫颈病变的感染者(对照组)作为研究对象。采集研究对象宫颈样本扩增HPV16L1序列并测序,分析病例组和对照组中HPV16各亚型的分布情况以及HPV16L1基因突变的分布情况,探讨HPV16L1基因变异与宫颈癌之间的关系。结果发现存在2种HPV16亚型分布,分别为亚洲型(As)和欧洲型(EUR),病例组中发现84例As亚型(94.4%),5例EUR亚型(5.6%),对照组发现122例As亚型(92.4%),10例EUR亚型(7.6%),经分析各亚型在病例组和对照组之间的分布差异无统计学意义,P=0.570。2个核苷酸的突变引起A6178C(N207T)和A7036C(K493T)氨基酸的改变,其中A6178C(N207T)突变仅发生在As亚型中,而A7036C(K493T)仅发生在EUR亚型中。结论通过HPV16L1基因的序列比对分析后发现,HPV16L1基因在宫颈癌和无宫颈病变的感染者中均存在变异,本研究结果可为基于HPV L1疫苗的研发设计提供参考数据。
OBJECTIVE Human papillomavirus type 16(HPV16)is one of main types of cervical cancer.Major capsid protein L1 of HPV16 could activate host immune cells and induce neutralizing antibodies.Investigating the relationship between HPV16 L1 gene mutation and cervical cancer.METHODS In the current study,a total of 89 HPV16-positive cervical cancer patients(case group)and 132 HPV16-positive asymptomatic individuals(control group)were enrolled in the Third Affiliated Hospital of Kunming Medical University from 2015 to 2017.HPV16 L1 gene was amplified and sequenced firstly,then,the distribution of HPV16 variants and HPV16 L1 gene mutations were investigated to explore the relationship between HPV16 L1 mutation and cervical cancer.RESULTS In the current study,two variants(As and EUR)were found in the case and control group(As variant 94.4%vs 92.4%,EUR variant 5.6%vs 7.6%in case and control groups respectively).The distribution of HPV16 showed no significant difference between the case and control groups(P=0.570).Two non-synonymous mutations were found(A6178 Cand A7036 C),and A6178 C(N207 T)occurred only in the As variants and A7036 C(K493 T)occurred only in the EUR variants.CONCLUSIONS There are mutations of HPV16 L1 gene in both case group and control group.Our results will be conducive to the design and development of HPV vaccine.
作者
戴书颖
周紫云
杨宏英
肖云
姚月婷
王侠
许金美
赵凌锋
严志凌
DAI Shu ying;ZHOU Zi-yun;YANG Hong-ying;XIAO Yun;YAO Yue ting;WANG Xia;XUJin mei;ZHAOLing feng;YAN Zhi-ling(School of Basic Medical Science,Kunming Medical University.K unming 650500,P.R.China;Schoo of Pharmaceutical Science&Yunnan Key Laboratory of Pharmacology for Natural Products,K unmning Medical Universily,K unming 650500,P.R.China;Institute of Medical Biology,Chinese Academy of Medical Sciences&Peking Union Medical College Kunming 650118,P.R.China;Third Affiliated Hospital of Kunming Medical University,K unming 650118,P.R.China)
出处
《中华肿瘤防治杂志》
CAS
北大核心
2020年第15期1189-1194,共6页
Chinese Journal of Cancer Prevention and Treatment
基金
国家自然科学基金(81573206)
云南省应用基础研究计划-昆明医科大学联合专项(2017FE467-077,-12)
云南省应用基础研究计划(2016FA034)。
